KrasLSL-G12D; Tp53fl/fl mice
KrasLSL-G12D; Tp53fl/fl mice are a genetically engineered mouse model widely used in cancer research, especially for studying tumors driven by oncogenic KRAS activation together with loss of TP53 function.
KrasLSL-G12D; Tp53fl/fl mice are a genetically engineered mouse model widely used in cancer research, especially for studying tumors driven by oncogenic KRAS activation together with loss of TP53 function. The model combines a conditional KRAS^LSL-G12D allele, which enables expression of mutant KRAS after Cre-mediated recombination, with TP53^fl/fl alleles, which permit tissue-specific deletion of TP53. This combination is a classic platform for modeling aggressive, TP53-deficient KRAS-driven malignancies and for testing therapeutic strategies in a genetically defined in vivo setting.
Biologically, the model is important because KRAS activation and TP53 loss cooperate to promote tumor initiation, progression, and treatment resistance. It is particularly relevant to pancreatic cancer biology, but it is also used more broadly to study oncogenic signaling, tumor microenvironment interactions, immune evasion, and response to targeted therapy. In recent studies, this mouse model has served as a preclinical system for evaluating interventions that affect KRAS-associated tumor growth, TP53-linked pathways, and immune-modulatory mechanisms, including approaches involving CD47, PCDH7, and other pathway-directed therapies.
Where the papers sit
17 papers from the last 6 months study KrasLSL-G12D; Tp53fl/fl mice directly · updated from PubMed 3 Oct 2026
Study type 0 clinical trials · 2 observational · 4 human data · 9 preclinical · 2 unclassified
Themes no clear themes
Those 17 do not share a common subject.
-
Cancer research, therapeutic discovery, organoid modeling, prognostic biomarker studies, and genome engineering appear together without a shared biological question. Individual papers address TP53 and KRAS alterations, ferroptosis, MDM2 and KRAS-pathway inhibition, patient-derived models, and editing methods. Endpoints range from drug response and tumor suppression to prognosis and editing efficiency. The group therefore supports no common direction beyond broad cancer and biotechnology relevance.
Papers
The 17 papers from the last 6 months that study KrasLSL-G12D; Tp53fl/fl mice directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (17)
- Transformation or Clonal Evolution? A Rare Case Report of Pulmonary Sarcomatoid Carcinoma Developing to Small Cell Lung Cancer. Thoracic cancer · 1 Jul 2026 PMID 42381179
- GC-MS based tentative identification of γ-sitosterol from Brassica nigra seeds and evaluation of its anticancer potential: An integrated in vitro and in silico study. PloS one · 29 Jun 2026 PMID 42371974
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. Science advances · 26 Jun 2026 PMID 42361179
- TP53 isoform dysregulation in pediatric B-ALL: identifying markers of favorable prognosis and relapse-associated dynamic. Molecular biology reports · 23 Jun 2026 PMID 42334648
- Prime editing-mediated microhomology enables efficient replacement of large DNA. Nucleic acids research · 22 Jun 2026 PMID 42328791
- Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 19 Jun 2026 PMID 42319734
- Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 19 Jun 2026 PMID 42318649
- Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages. Apoptosis : an international journal on programmed cell death · 17 Jun 2026 PMID 42307815
- Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
- Discovery of an Indole-Based p53-Y220C Reactivator with In Vivo Antitumor Activity via Structure-Guided Design. Journal of medicinal chemistry · 10 Jun 2026 PMID 42268678
- Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma. Lung cancer (Amsterdam, Netherlands) · 30 May 2026 PMID 42217423
- Integrated multi-stage screening assisted discovery and optimization of spirooxindole MDM2 inhibitors. Journal of molecular graphics & modelling · 26 May 2026 PMID 42190581
- Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274
- KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Cancer research · 29 Apr 2026 PMID 42054558
- Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors. Biochemical and biophysical research communications · 18 Apr 2026 PMID 42000628
By study type
Observational studies and case reports (2)
- Transformation or Clonal Evolution? A Rare Case Report of Pulmonary Sarcomatoid Carcinoma Developing to Small Cell Lung Cancer. Thoracic cancer · 1 Jul 2026 PMID 42381179
- Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma. Lung cancer (Amsterdam, Netherlands) · 30 May 2026 PMID 42217423
Human data, design not indexed (4)
- Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. Science advances · 26 Jun 2026 PMID 42361179
- TP53 isoform dysregulation in pediatric B-ALL: identifying markers of favorable prognosis and relapse-associated dynamic. Molecular biology reports · 23 Jun 2026 PMID 42334648
- Integrated multi-stage screening assisted discovery and optimization of spirooxindole MDM2 inhibitors. Journal of molecular graphics & modelling · 26 May 2026 PMID 42190581
- Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
Preclinical: animal, cell and lab studies (9)
- GC-MS based tentative identification of γ-sitosterol from Brassica nigra seeds and evaluation of its anticancer potential: An integrated in vitro and in silico study. PloS one · 29 Jun 2026 PMID 42371974
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Prime editing-mediated microhomology enables efficient replacement of large DNA. Nucleic acids research · 22 Jun 2026 PMID 42328791
- Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 19 Jun 2026 PMID 42319734
- Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages. Apoptosis : an international journal on programmed cell death · 17 Jun 2026 PMID 42307815
- Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
- Discovery of an Indole-Based p53-Y220C Reactivator with In Vivo Antitumor Activity via Structure-Guided Design. Journal of medicinal chemistry · 10 Jun 2026 PMID 42268678
- KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Cancer research · 29 Apr 2026 PMID 42054558
- Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors. Biochemical and biophysical research communications · 18 Apr 2026 PMID 42000628
Unclassified: not yet indexed with MeSH (2)
- Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 19 Jun 2026 PMID 42318649
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-20. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.